Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Safety screening in early drug discovery: An optimized assay panel.

Bendels S, Bissantz C, Fasching B, Gerebtzoff G, Guba W, Kansy M, Migeon J, Mohr S, Peters JU, Tillier F, Wyler R, Lerner C, Kramer C, Richter H, Roberts S.

J Pharmacol Toxicol Methods. 2019 Jul 5:106609. doi: 10.1016/j.vascn.2019.106609. [Epub ahead of print]

PMID:
31284073
2.

Can we discover pharmacological promiscuity early in the drug discovery process?

Peters JU, Hert J, Bissantz C, Hillebrecht A, Gerebtzoff G, Bendels S, Tillier F, Migeon J, Fischer H, Guba W, Kansy M.

Drug Discov Today. 2012 Apr;17(7-8):325-35. doi: 10.1016/j.drudis.2012.01.001. Epub 2012 Jan 16. Review.

PMID:
22269136
3.

Bovine papillomavirus type 1 DNA replication: the transcriptional activator E2 acts in vitro as a specificity factor.

Bonne-Andréa C, Tillier F, McShan GD, Wilson VG, Clertant P.

J Virol. 1997 Sep;71(9):6805-15.

4.

Bovine papillomavirus E1 protein binds specifically DNA polymerase alpha but not replication protein A.

Bonne-Andrea C, Santucci S, Clertant P, Tillier F.

J Virol. 1995 Apr;69(4):2341-50.

5.
6.

Catabolite modulator factor: physiological properties and in vivo effects.

Dessein A, Tillier F, Ullmann A.

Mol Gen Genet. 1978 Jun 1;162(1):89-94.

PMID:
209310
7.

Catabolite modulator factor: a possible mediator of catabolite repression in bacteria.

Ullmann A, Tillier F, Monod J.

Proc Natl Acad Sci U S A. 1976 Oct;73(10):3476-9.

Supplemental Content

Loading ...
Support Center